Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
1 finding from 1 review
Knee pain (short term) VAS scale: 0 to 10; higher score = worse pain. · adult participants with patellar tendinopathy
1 finding from 1 review
Participant global assessment of success Not measured · adult participants with patellar tendinopathy
1 finding from 1 review
Quality of life · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · adult participants with patellar tendinopathy
1 finding from 1 review
Adverse event · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tendon rupture · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional outcomes · adult participants with patellar tendinopathy
1 finding from 1 review